BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析

◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1647
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥18,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥55,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

BioMarin Pharmaceutical Inc (BMRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Apr 21,2020 BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26,2020 BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03,2020 BioMarin announces CFO succession
Dec 10,2019 Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioMarin Pharmaceutical Inc – Key Facts
BioMarin Pharmaceutical Inc – Key Employees
BioMarin Pharmaceutical Inc – Key Employee Biographies
BioMarin Pharmaceutical Inc – Major Products and Services
BioMarin Pharmaceutical Inc – History
BioMarin Pharmaceutical Inc – Company Statement
BioMarin Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
BioMarin Pharmaceutical Inc – Business Description
Product Category: Aldurazyme
Overview
Performance
Product Category: Brineura
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan
Overview
Performance
Product Category: Naglazyme
Overview
Performance
Product Category: Palynziq
Overview
Performance
Product Category: Vimizim
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc – Corporate Strategy
BioMarin Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
BioMarin Pharmaceutical Inc – Strengths
BioMarin Pharmaceutical Inc – Weaknesses
BioMarin Pharmaceutical Inc – Opportunities
BioMarin Pharmaceutical Inc – Threats
BioMarin Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 21, 2020: BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26, 2020: BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03, 2020: BioMarin announces CFO succession
Dec 10, 2019: Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias
Oct 23, 2019: BioMarin announces third quarter 2019 financial results
Oct 07, 2019: BioMarin promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
Aug 01, 2019: BioMarin announces second quarter 2019 Financial Results
Jul 09, 2019: BioMarin appoints pharmaceutical veteran and former J & J executive, Liz McKee Anderson, to Board of Directors
Apr 25, 2019: BioMarin announces first quarter 2019 financial results
Feb 21, 2019: BioMarin announces full year and fourth quarter 2018 results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
BioMarin Pharmaceutical Inc, Performance Chart (2015 - 2019)
BioMarin Pharmaceutical Inc, Ratio Charts
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Glythera Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Glythera Ltd (Glythera) is a biotechnology company that focuses on the development of antibody drug conjugates (ADCs) and biotherapeutics for the treatment of cancer. The company develops antibody-based therapies for the treatment of cancer and broader based therapeutics. It uses its proprie …
  • Banco Santander SA:戦略・SWOT・企業財務分析
    Banco Santander SA - Strategy, SWOT and Corporate Finance Report Summary Banco Santander SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • MiMedx Group Inc (MDXG):企業の財務・戦略的SWOT分析
    Summary MiMedx Group Inc (MiMedx) is a biopharmaceutical company that develops, manufactures and markets regenerative biologics utilizing human placental allografts. The company provides products such as amniotic membrane, umbilical cord, placental ECM and amniotic fluid. It utilizes proprietary pur …
  • Modern India Ltd:企業の戦略・SWOT・財務情報
    Modern India Ltd - Strategy, SWOT and Corporate Finance Report Summary Modern India Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Transport for London:企業の戦略的SWOT分析
    Transport for London - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Lixil Group Corporation (5938):企業の財務・戦略的SWOT分析
    Lixil Group Corporation (5938) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Hargreaves Services Plc:企業の戦略・SWOT・財務分析
    Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report Summary Hargreaves Services Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • North Central Electric Cooperative, Inc.:発電所・企業SWOT分析
    North Central Electric Cooperative, Inc. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, informa …
  • SJVN Ltd (SJVN):企業の財務・戦略的SWOT分析
    SJVN Ltd (SJVN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • Anchiano Therapeutics Ltd (BICL):製薬・医療:M&Aディール及び事業提携情報
    Summary Anchiano Therapeutics Ltd (Anchiano) formerly BioCancell Ltd, focuses on the identification, development and commercialization of therapies for diagnosis and treatment of cancer-related diseases such as superficial bladder carcinoma, pancreatic cancer and ovarian cancer. The company's produc …
  • Patterson Companies, Inc.:企業の戦略・SWOT・財務分析
    Patterson Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary Patterson Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Fiskars Corporation:企業の戦略・SWOT・財務情報
    Fiskars Corporation - Strategy, SWOT and Corporate Finance Report Summary Fiskars Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • QT Vascular Ltd (5I0):医療機器:M&Aディール及び事業提携情報
    Summary QT Vascular Ltd (QT Vascular) is a medical device manufacturing company that offers developing, manufacturing and distributing of advanced therapeutic solutions for the treatment of complex vascular diseases. The company’s products include coronary products such as Chocolate PTCA Balloon Cat …
  • Xped Limited (XPE)-石油・ガス分野:企業M&A・提携分析
    Summary Xped Limited (Xped) formerly Raya Group Limited, is an Internet of Things company that develops software and hardware solutions. It offers auto discovery remote control, Xerts, and Xped app software; and hardware such as Xped ADRC Shields, Umbo-Xped ADRC Hub, UltraPlug, VariPlug, IRBlaster. …
  • Kangmei Pharmaceutical Co Ltd (600518):製薬・医療:M&Aディール及び事業提携情報
    Summary Kangmei Pharmaceutical Co Ltd (Kangmei) is a manufacturer and distributor of herbal medicine. The company provides herbal raw materials and preparations. Kangmei products include Chinese herbal medicine, bottled single product, hong mei life, xinkaihe senate, chinese medicine derived, medici …
  • Cevec Pharmaceuticals GmbH-製薬・医療分野:企業M&A・提携分析
    Summary Cevec Pharmaceuticals GmbH (Cevec) is a healthcare products company that offers production of biopharmaceuticals. The company produces recombinant glycoproteins and gene therapy vectors. It utilizes its CAP-Go technology developed expression system based on human cells, for the production of …
  • The Bank of East Asia, Limited:企業のM&A・事業提携・投資動向
    The Bank of East Asia, Limited - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Bank of East Asia, Limited Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers a …
  • Econocom Group SA (ECONB):企業の財務・戦略的SWOT分析
    Econocom Group SA (ECONB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Ameriprise Financial, Inc.:企業の戦略・SWOT・財務分析
    Ameriprise Financial, Inc. - Strategy, SWOT and Corporate Finance Report Summary Ameriprise Financial, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Park Hotels & Resorts Inc (PK):企業の財務・戦略的SWOT分析
    Park Hotels & Resorts Inc (PK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆